Coeptis Receives Shareholder Approval Towards Z Squared Merger
MWN-AI** Summary
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), a next-gen biopharmaceutical company, announced on February 5, 2026, that its shareholders approved the merger with Z Squared Inc., which will transform Z Squared into a wholly-owned subsidiary of Coeptis. The vote occurred on January 30, 2026, and while the merger awaits completion of certain closing conditions, it marks a significant step in Coeptis’ growth trajectory.
Coeptis, with subsidiaries including Coeptis Pharmaceuticals and GEAR Therapeutics, focuses on developing innovative cell therapy platforms addressing cancer, autoimmune, and infectious diseases. Its technological advancements include an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy, alongside collaborations with institutions like the University of Pittsburgh for CAR therapy developments. The company is also enhancing operational capabilities through a newly established Technology Division, which incorporates AI and robotic process automation tools aimed at optimizing business efficiencies.
Z Squared, by contrast, specializes in securing Dogecoin (DOGE) and Litecoin (LTC) networks through large-scale mining operations. Post-merger, Z Squared will become the largest publicly traded Dogecoin miner in the U.S. with 9,800 ASIC miners situated across multiple states. The company emphasizes efficient cash flows, converting mined assets into USD or stablecoins swiftly to maintain a disciplined investment approach.
As both companies move forward with the merger, they invite investors to review further details available in the SEC filings and advise caution regarding forward-looking statements due to inherent uncertainties in projections. For more information, stakeholders are encouraged to visit Coeptis' website or reach out through investor relations contacts.
MWN-AI** Analysis
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has received shareholder approval for its merger with Z Squared Inc., likely marking a pivotal moment for both companies. This merger combines a biopharmaceutical entity focused on cell therapies with a cryptocurrency mining company, particularly in the Dogecoin and Litecoin realms.
For investors in Coeptis, this merger introduces a diversified operational model. While historically focused on biopharmaceuticals, Coeptis is now poised to augment its portfolio with Z Squared's institutional-scale digital infrastructure. Given the growing interest in cryptocurrency and blockchain technologies, Z Squared's mining operations may provide Coeptis with a unique revenue stream, further stabilizing its financial outlook.
Prospective investors should take advantage of the anticipated synergy between the companies’ distinct operations. Coeptis brings cutting-edge biopharmaceutical innovations, including promising therapeutic platforms and a commitment to regulatory compliance. In contrast, Z Squared’s well-structured cryptocurrency mining strategy emphasizes efficiency and rapid conversion of mined assets to liquid funds. This dual focus could mitigate some risks typically associated with both sectors individually.
Nevertheless, investors should remain cautious. The biopharmaceutical industry is notoriously volatile, subject to regulatory scrutiny and R&D uncertainties. Similarly, the cryptocurrency market's inherent risks can impact profitability, affected by regulatory changes and market dynamics.
As Coeptis approaches the closing of this merger, investors ought to conduct comprehensive due diligence. Monitoring the integration process and the operational performance of Z Squared will be critical. For those considering entering or adding to their positions in Coeptis, a careful analysis of emerging market trends and the respective performance metrics of both entities post-merger will be crucial in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that its shareholders have voted to approve the previously announced merger with Z Squared Inc.
The transaction was approved on January 30, 2026, by Coeptis’ shareholders. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis. The transaction remains subject to satisfaction of the remaining conditions to closing.
Additional details regarding the shareholder vote and the proposed merger are included in the Company’s Form 8-K filed with the SEC, which is available on the SEC’s website at www.sec.gov, and in the Investor Relations section of the Company’s website at investors.coeptistx.com.
About Coeptis:
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com.
About Z Squared:
Z Squared is a digital infrastructure company focused on securing the Dogecoin (DOGE) and Litecoin (LTC) networks through institutional-scale mining operations. Upon closing of the merger, Z Squared is expected to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa, making it the largest publicly-traded pure-play Dogecoin miner in the United States.
Z Squared's operational model emphasizes efficiency, discipline, and risk management. Mined assets are converted to USD or stablecoins typically within 24 hours, aligning with a cash-flow-focused strategy rather than speculative holding. The company is led by an experienced team with deep expertise in cryptocurrency mining operations and infrastructure management.
Participants in the Solicitation
Coeptis, Z Squared Inc. and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis’ and Z Squared’s stockholders with respect to the proposed Transaction. Investors and securityholders may obtain more detailed information regarding the names and interests in the Transaction of the directors and officers of each of Coeptis and Z Squared in the proxy statement/prospectus for the proposed Transaction as field with the SEC, including the Registration Statement.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed Transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Coeptis’ filings with the U.S. Securities and Exchange Commission, including the Registration Statement, which are available for review at www.sec.gov. Neither Coeptis nor Z Squared undertake any obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
Investor Relations Contacts:
FAQ**
What strategic advantages does Coeptis Therapeutics Inc COEP expect to gain from the acquisition of Z Squared, particularly in the context of its biopharmaceutical focus and innovative cell therapy platforms?
How will the merger with Z Squared impact Coeptis Therapeutics Inc COEP's research and development efforts, especially regarding its collaboration with institutions like the University of Pittsburgh on CAR technology?
What are the expected financial implications for Coeptis Therapeutics Inc COEP post-merger, given Z Squared’s model of converting mined assets to USD or stablecoins quickly?
How does Coeptis Therapeutics Inc COEP plan to integrate Z Squared's digital infrastructure capabilities into its existing operations, particularly in enhancing its regulatory compliance and patient care standards?
**MWN-AI FAQ is based on asking OpenAI questions about Coeptis Therapeutics Inc (NASDAQ: COEP).
NASDAQ: COEP
COEP Trading
-0.56% G/L:
$12.48 Last:
23,053 Volume:
$12.46 Open:
